Ran Nussbaum
CIK: 0001609805
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 3, 2026LBRX
LB PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
10K shares- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
Conversion(C)Indirect411.7K shares- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
Purchase(P)Indirect1M shares at avg. $15.00$15.0M - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
22.4K shares- - Jun 4, 2025KROS
Keros Therapeutics, Inc.
Award(A)Direct5.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 |  LBRX LB PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Conversion(C) | 411,681 | - | - | Indirect |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Purchase(P) | 1,000,000 | $15.00 | $15,000,000 | Indirect |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 22,449 | - | - | Direct |
| Jun 4, 2025 |  KROS Keros Therapeutics, Inc. | Award(A) | 5,250 | - | - | Direct |
1-5 of 5 transactions
About Nussbaum Ran
Nussbaum Ran (SEC CIK 0001609805) files insider reports with the SEC as Director of LB PHARMACEUTICALS INC (LBRX) and Director of Keros Therapeutics, Inc. (KROS).
Signal8 holds 6 ownership filings by Nussbaum Ran (1 Form 3, 5 Form 4), filed between Jun 6, 2025 and Jun 5, 2026. Those filings report 5 transactions, from Jun 4, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Nussbaum Ran's filings is in NEW YORK, NY.
Recent filings by Nussbaum Ran
- Jun 3, 2026: Grant or award of LBRX derivative securities (Form 4, code A).
- Sep 12, 2025: Conversion of LBRX shares (Form 4, code C).
- Sep 12, 2025: Open-market purchase of LBRX shares (Form 4, code P).
- Sep 10, 2025: Grant or award of LBRX derivative securities (Form 4, code A).
- Jun 4, 2025: Grant or award of KROS shares (Form 4, code A).
Other insiders filing for LB PHARMACEUTICALS INC (LBRX)
- Miller Joseph M, Chief Financial Officer
- Kozauer Susan Gani, Chief Medical Officer
- Deep Track Biotechnology Master Fund, Ltd., 10% Owner
- RUFFOLO ROBERT R, Director
- Luse Rebecca, Director
- Lenz Robert A., Director